Cyclerion Therapeutics, Inc. Common Stock
CYCNCyclerion Therapeutics, Inc. (CYCN) is a clinical-stage biotechnology company focused on developing innovative therapies for cognitive and neurological disorders. The company leverages its neuroscience platform to identify and advance novel compounds aimed at enhancing cognitive function and treating serious neurological conditions.
Company News
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq...
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. The Singing Machine Company, Inc. (NASDAQ: MICS) surged 73% to $1.81 after the company announced termination of its at-the-market equity program. Applied Digit...
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023. The ...
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors
